Invisicare® – Advanced Polymer Drug Delivery

Technology

Transdermal Innovation for Obesity & Glucose Control

Obesity Treatments

Advanced Dermatology & Rare Skin Disease Treatments

Dermatology

Patent-Protected Innovation in Drug Delivery

Our Patents

Innovative Drug Delivery

& Strategic Partnerships for Advanced Therapeutics

At Skinvisible Pharmaceuticals, Inc., we leverage our expertise in drug delivery development to build a superior pipeline of topical and transdermal products, focused in dermatology, obesity and glucose management as well as expanding into other therapeutic areas.

Our Invisicare delivery technology is the backbone of our formulations. Protected by patents and trade secrets, our proprietary delivery system can deliver the results.
Through strategic licensing partnerships, we bring these innovations to market with leading pharmaceutical and healthcare companies worldwide that are seeking new advanced products, product enhancements or life cycle management for their existing products.

Our licensees

Our

Management Team

Terry Howlett
President & Chief Executive Officer
Doreen McMorran
Vice President, Business Development
James A. Roszell, PhD
Head, Research & Development

News

Releases

ovation-corporate
September 18, 2025

Ovation Science and Skinvisible Strengthen Partnership in Obesity Market with New Cannabinoid Delivery Patents

Ovation Science and Skinvisible Pharmaceuticals have expanded their partnership to advance patent-pending Invisicare® cannabinoid delivery technology for obesity and metabolic health. The collaboration leverages THC-V research, new patent protection, and the growing US$150B obesity therapy market.
Read Press Release
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
January 23, 2025

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Skinvisible Pharmaceuticals announces major progress in 2024-2025 through its licensee, Quoin Pharmaceuticals, in developing QRX003 for Netherton Syndrome using Invisicare technology. With FDA clearance, global clinical trials, and regulatory success, Skinvisible advances innovative topical and transdermal therapies.
Read Press Release
Skinvisible Proprietary Transdermal Obesity Formulation Development 2025
October 3, 2024

Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development

Skinvisible Pharmaceuticals publishes groundbreaking research on transdermal obesity drug delivery using Invisicare technology. The study shows 99.6% transdermal penetration of GLP-1 actives, offering a non-invasive alternative to injections. Skinvisible seeks partnerships to bring transdermal obesity therapies to market.
Read Press Release
Promising Data on Transdermal Obesity Formulations
July 9, 2024

Skinvisible Unveils Promising Data on Transdermal Obesity Formulations

Skinvisible Pharmaceuticals announces breakthrough data on transdermal obesity drug delivery using Invisicare technology. Studies show up to 69% drug penetration, offering a non-invasive alternative to injections. Skinvisible seeks partners to bring transdermal obesity therapies to market.
Read Press Release
Obesity Patent Application for Transdermal Delivery
June 24, 2024

Skinvisible Expands Obesity Patent Application for Transdermal Delivery

Skinvisible Pharmaceuticals expands its obesity patent application for transdermal drug delivery using Invisicare technology. The innovation enhances systemic absorption of GLP-1 agonists, CB-1 antagonists, and SGLT-2 inhibitors, offering a needle-free alternative. Skinvisible seeks partners to bring this breakthrough to market.
Read Press Release
Obesity Patent for Advanced Transdermal Treatment
May 29, 2024

Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

Skinvisible Pharmaceuticals files a provisional patent for transdermal obesity drug delivery using Invisicare technology. This needle-free, topical solution enhances drug absorption and patient compliance, revolutionizing obesity treatment. Skinvisible seeks partners to bring this innovation to market.
Read Press Release

Our Newsletter

Receive the latest news and insights to your inbox.